Key result
Review summarizes key myocarditis diagnosis, therapy, and follow-up updates from recent ESC guidelines.
Why the study?
Myocarditis remains an unknown disease with varying clinical manifestations often leading to heart failure, and recent 2021 and 2022 ESC guidelines provided the first official European updates on its diagnosis and treatment since 2013.
This review provides an updated overview of myocarditis management based on the latest ESC guidelines and recent research.
Offers clinicians an ESC-aligned myocarditis summary; leaves open prospective validation of management advances.
Myocarditis remains an unknown disease with varying clinical manifestations, often leading to heart failure. The latest 2021 and 2022 guidelines of the European Society of Cardiology (ESC) are the first official European documents updating knowledge on the diagnosis and treatment of myocarditis since the 2013 ESC expert consensus statement. These guidelines and new studies allow standardization and improvements to the management of myocarditis. In this review, we discuss the most important aspects of myocarditis diagnosis, therapies and follow-up based on current knowledge.
No takes yet. Share an insight, caveat, or question.
Chabior et al. (2024) conducted a review in Myocarditis. This review summarizes the most important aspects of myocarditis diagnosis, therapies, and follow-up based on the 2021 and 2022 European Society of Cardiology guidelines and recent studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: